Cantor Fitzgerald downgrades Avalon Pharmaceuticals (NASDAQ: AVRX) from Buy to Hold and lowers their price target from $5.50 to $1.50.
This article: 191 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE